Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Zhao, Jun ^a   Zhao, Mingfang ^a   Jin, Bo ^a   Yu, Ping ^a   Hu, Xuejun ^a   Teng, Yuee ^a   Zhang, Jingdong ^a   Luo, Ying ^a   Zhang, Lingyun ^a   Zheng, Shuang ^a   Zhou, Qiyin ^a   Li, Heming ^a   Liu, Yunpeng ^a   Qu, Xiujuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Hyperfibrinogenemia; NSCLC

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FIBRINOGEN; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD PROTEIN DISORDER; CANCER CHEMOTHERAPY; CANCER POST CHEMOTHERAPY; CANCER PRE CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CONTROL; EASTERN COOPERATIVE ONCOLOGY GROUP SCORE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; HUMAN; HUMAN TISSUE; HYPERFIBRINOGENEMIA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; FIBRINOGEN; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864413206     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-330     Document Type: Article

References (43)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, . Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advaced non-small cell lung cancer. N Eng J Med 2002, 346(2):92-98. Eastern Cooperative Oncology Group.
2. Ardizzoni A, Boni L, Tiseo M. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99(11):847-857. 10.1093/jnci/djk196, 17551145.
3. Rosell R, Lord R, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002, 38:217-227. 10.1016/S0169-5002(02)00224-6, 12445742.
4. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, . IALT Bio Investigators DNA repair by ERCCI in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. The New Engl J Med 2006, 355:983-991. IALT Bio Investigators.
5. Ryu JS, Shin ES, Nam HS, Yi HG, Cho JH, Kim CS, Kim HJ, Lee JE. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. J Thorac Oncol 2011, 6:1320-1329. 10.1097/JTO.0b013e3182208e26, 21642870.
6. Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, Hatipoglu ON, Caglar T. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol) 2007, 19:494-498.
7. Batschauer A, Figueiredo C, Bueno E, Ribeiro M, Dusse L, Fernandes A, Gomes K, Carvalho M. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol 2010, 21:1267-1272. 10.1093/annonc/mdp474, 19880435.
8. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prové A, Lemmens J, Vermeulen P. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002, 86:389-395. 10.1038/sj.bjc.6600069, 2375200, 11875705.
9. Kwon H, Oh S, Lee S, Kim S, Han JY, Koh RY, Kim MC, Kim H. Plasma Levels of Prothrombin Fragment F1 + 2, D-dimer and Prothrombin Time Correlate with Clinical Stage and Lymph Node Metastasis in Operable Gastric Cancer Patients. Jpn J Clin Oncol 2008, 38:2-7. 10.1093/jjco/hym157, 18258711.
10. Kilic M, Yoldas O, Keskek M, Ertan T, Tez M, Gocmen E, Koc M. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis 2008, 10:238-241. 10.1111/j.1463-1318.2007.01374.x, 17868411.
11. Pedersen L, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Resp J 1996, 9:1826-1830.
12. Tennent GA, Brennan SO, Stangou AJ, Grady JO, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood 2007, 109:1971-1974. 10.1182/blood-2006-08-040956, 17082318.
13. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005, 70:247-299.
14. Brown LF, Water L, Harvey VS, Dvorak HF. Fibrinogen Influx and Accumulation of Cross-linked Fibrin in Healing Wounds and in Tumor Stroma. Am J Pathol 1988, 130:455-465. 1880682, 3279791.
15. Jensen T, Kierulf P, Sandset P, Klingenberg O, Godal H. Fibrinogen and fibrin induce synthesis of pro- inflammatory cytokines from isolated peripheral blood mononuclear cells. Thromb Haemost 2007, 20:822-829.
16. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Resp J 2001, 17:667-673.
17. Buccheri G, Ferrigno C, Ginardi, Zuliani C. Haemostatic Abnormalitities in Lung Cancer: Prognosic Implications. Eur J Cancer 1997, 33:50-55. 10.1016/S0959-8049(96)00310-3, 9071899.
18. Jones J, McGonigle N, McAnespie M, Cran G, Graham A. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006, 53:97-101. 10.1016/j.lungcan.2006.03.012, 16698114.
19. Guo Q, Zhang B, Dong X. Elevated Levels of Plasma Fibrinogen in Patients With Pancreatic Cancer. Pancreas 2009, 38:75-79.
20. Yamashita H, Kitayama J, Nagawa H. Hyperfibrinogenemia is a Useful Predictor for Lymphatic Metastasis in Human Gastric Cancer. Jpn J Oncol. 2005, 35:595-600.
21. Yamashita H, Kitayama J, Kanno N, Yatomi Y, Nagawa H. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 2006, 6:147. 10.1186/1471-2407-6-147, 1501042, 16740157.
22. Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J. High Preoperative Plasma Fibrinogen Levels Are Associated With Distant Metastases and Impaired Prognosis After Curative Resection in Patients With Colorectal Cancer. J of Sur Oncol 2010, 102:428-432.
23. Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, Kubochi K, Kitajima M, Matsumoto S. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 2007, 22:2222-2227. 10.1111/j.1440-1746.2006.04736.x, 18031385.
24. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 2010, 102:952-956. 10.1038/sj.bjc.6605547, 2844023, 20160724.
25. Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L. Plasma Fibrinogen Levels and Prognosis in Patients with Ovarian Cancer: A Multicenter Study. Oncologist 2009, 14:979-985. 10.1634/theoncologist.2009-0079, 19776095.
26. Polterauer S, Seebacher V, Hefler-Frischmuth K, Grimm C, Heinze G, Tempfer C, Reinthaller A, Hefler L. Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol 2009, 200:647-648.
27. Kawai K, Kitayama J, Tsuno NH, Sunami E, Nagawa H. Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer. Int J Colorectal Dis 2011, 26:45-51. 10.1007/s00384-010-1054-y, 20809424.
28. Milroy R, Douglas JT, Campbell J, Carter R, Dolowe G, Banham SW. Abnormal haemostasis in small cell lung cancer. Thorax 1988, 43:978-981. 10.1136/thx.43.12.978, 461606, 2467397.
29. Meehan KR, Zacharski LR, Moritz TE, Rickles FR. Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of Veterans Affairs Cooperative Study 188. Am J Hematol 1995, 49:143-148. 10.1002/ajh.2830490208, 7771466.
30. Zecchina G, Ghio P, Bosio S, Cravino M, Camaschella C, Scagliotti G. Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 2007, 8:264-270. 10.3816/CLC.2007.n.004, 17311691.
31. Fidller I, Ellis L. The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79:315-328. 10.1016/0092-8674(94)90200-3, 7525077.
32. Wang X, Wang E, Kavanagh J, Freedman R. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005, 3:25. 10.1186/1479-5876-3-25, 1182397, 15969748.
33. Fearon K, Barber M, Falconer J, McMillan D, Ross J, Preston T. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 1999, 23:584-588. 10.1007/PL00012351, 10227928.
34. Amrani D. Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. Blood Coagul Fibrinolys 1990, 1:443-446.
35. Zhang Z, Fuller G. Interleukin 1beta inhibits interleukin 6-mediated rat gamma fibrinogen gene expression. Blood 2000, 96:3466-3472.
36. Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002, 48:1931-1937.
37. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Decline serum carcinomebryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non small cell lung cancer. Cancer 2006, 107:2842-2849. 10.1002/cncr.22330, 17103443.
38. Susana C, Isaac N, Marina L, Pablo M, Eva C, Davis T, Enriqueta F. Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer 2011, 12:172-179. 10.1016/j.cllc.2011.03.019, 21663860.
39. Trapé J, Buxo J, Pérez De Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 2003, 23:4277-4281.
40. Jin B, Huang AM, Zhong RB, Han BH. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer. Chemotherapy 2010, 56:417-423. 10.1159/000317580, 21079400.
41. Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced nonsmall cell lung cancer: a prospective analysis. BMC Cancer 2009, 9:119. 10.1186/1471-2407-9-119, 2679041, 19386089.
42. Załeska M, Szturmowicz M, Zych J, Roszkowska-Sliz B, Demkow U, Langfort R, Roszkowski-Sliz K. Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival. Pneumonol Alergol Pol 2010, 78:14-20.
43. American Thoracic Society and European Respiratory Society Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med 1997, 156:320-332. American Thoracic Society and European Respiratory Society.